GLP-1 drugs are everywhere, but what does that actually mean?

What's this video probably claiming?

A dermatologist noticing that a large share of their patient panel is now on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) isn't just making small talk. The caption frames this as an "epidemic," which in the TikTok health space usually signals one of a few things: concern about overprescribing, fascination with how fast adoption has moved, or a setup for discussing downstream effects on skin, hair, or body composition that a derm would plausibly see. Given the creator's specialty, this is probably a discussion of GLP-1 side effects that show up in dermatology practice, things like hair shedding (telogen effluvium), "Ozempic face" (rapid volume loss), or skin laxity after significant weight loss. The "taking over" framing is hyperbole, but it gestures at something real: GLP-1 prescriptions have grown faster than almost any drug class in recent memory, and clinicians across specialties are now managing patients on these drugs whether they expected to or not.

What does the science actually show?

The clinical trial data on semaglutide and tirzepatide is genuinely strong for weight loss outcomes. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity. For semaglutide 2.4mg, the STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean weight loss over 68 weeks. These aren't marginal numbers. But the side effect profile is real and often undersold. In STEP 1, 44% of participants reported nausea, 32% reported diarrhea, and discontinuation due to adverse events ran about 7%. Hair loss specifically, which a dermatologist would care about, has been reported in roughly 3% of participants in semaglutide trials, almost certainly reflecting telogen effluvium triggered by rapid caloric restriction and physiological stress rather than a direct drug mechanism. The distinction matters clinically because the treatment approach differs.

Where does the social media noise diverge from clinical reality?

The "Ozempic epidemic" framing flattens a genuinely complex prescribing picture. On TikTok, GLP-1 content tends to split into two camps: uncritical enthusiasm ("I lost 40 pounds, here's my journey") and moral panic ("everyone's taking shortcuts"). Both miss the actual clinical nuance. First, the majority of GLP-1 prescriptions are still for type 2 diabetes, not cosmetic weight loss. Second, the dermatological effects being discussed in clinic, specifically volume loss in the face and neck, are not a drug toxicity. They are a consequence of losing 15 to 20 percent of body weight quickly, something that would happen with any effective intervention including bariatric surgery. Third, "Ozempic face" has no clinical definition and is not a recognized diagnosis. It has been amplified by plastic surgeons marketing filler treatments, which is its own conflict of interest worth naming. Creators who blur the line between a drug side effect and a consequence of weight loss do their audiences a disservice.

What should you actually know?

If you're on a GLP-1 agonist or considering one, a few things are worth understanding clearly. Hair shedding, if it happens, typically peaks around three to six months and resolves without stopping the medication, because the trigger is the nutritional stress of rapid weight loss, not the drug itself. Adequate protein intake, generally 1.2 to 1.6 grams per kilogram of body weight, and resistance training are the two levers that most strongly predict lean mass preservation during GLP-1-assisted weight loss, per data from Bikou et al., 2023, and earlier work by Barakat et al., 2020 in Strength and Conditioning Journal. Skin laxity after significant weight loss is real and largely proportional to the amount and speed of weight lost, and to age and skin elasticity at baseline. A dermatologist seeing more of these patients is genuinely relevant clinical context. That said, calling it an epidemic because a drug class is working well enough that millions of people are using it is a framing choice, not a medical assessment.